Select Language
CEACAM-5
CEACAM-5 Overview
| English Name | Carcinoembryonic antigen related cell adhesion molecule 5 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 18 | Target Synonym | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Carcinoembryonic antigen related cell adhesion molecule 5 |
| Target Synonym | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 18 |
| Highest Development Stage | Phase 3 Clinical |
CEACAM-5 Product List
- Product Category
Protein (18)Cell (2)Cell Grade Beads (1)Beads (1)
- Product Status
Launched (22)
- Species
Human (16)Mouse (2)Cynomolgus (3)Rhesus macaque (1)
- Tag
His Tag (8)His Tag & Avi Tag (4)Fc Tag (3)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (4)
- Conjugate
Unconjugated (11)Biotin-labeled (5)FITC Labeled (2)- (4)
Add to Cart
Total: 22
- 1
- 2
- 3
CEACAM-5 Background
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.
CEACAM-5 Synonyms
CEACAM-5,CD66e,CEA,Meconium antigen 100
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Brain Diseases; Brain metastases; Brain Neoplasms; Colonic Diseases; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Intestinal Diseases; Intestinal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| NEO-201 | NEO-201 | Phase 2 Clinical | National Cancer Institute, Precision Biologics Inc | Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Colorectal Neoplasms; Liver Neoplasms | Details | |
| BMS-986490 | BMS-986490 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details |
| LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Neoplasms; Solid tumours | Details |
| Precemtabart tocentecan | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
| anti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics) | Phase 1 Clinical | Shanghai Simcere Pharmaceutical Co Ltd | Colorectal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Small Intestine Cancers; Solid tumours; Stomach Neoplasms | Details | |
| 125-Iodine-labeled MFE-23 | Phase 1 Clinical | Cancer Research UK | Neoplasms | Details | |
| anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Adenocarcinoma; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details | |
| CEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company) | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details | |
| 124I-M5A | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Colorectal Neoplasms | Details | |
| IBI-3020 | IBI3020; IBI-3020 | Phase 1 Clinical | Xinda Biomedical Technology (Hangzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SGN-CEACAM5C | PF-08046050; SGN-CEACAM5C; SAR445953; SAR-445953 | Phase 1 Clinical | Sanofi, Seagen Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms | Details |
| EBC-129 | EBC129; EBC-129 | Phase 1 Clinical | Experimental Drug Development Centre | Solid tumours | Details |
| GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | Colonic Neoplasms | Details |
Product Reviews
n***l2026-08-21
0People LikeThis protein was purchased for target testing. The product was very easy to reconstitute and produced accurate results. The shipping speed of the product was more efficient than estimated which was greatly appreciated. We enjoy ordering high quality products from Acro.
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland